AI Verdict
MSFT has stronger fundamentals based on our AI analysis.
PCRX vs MSFT Fundamental Comparison
| Metric | PCRX | MSFT |
|---|---|---|
| Revenue | $726.4M | $158.9B |
| Net Income | $7.0M | $66.2B |
| Net Margin | 1.0% | 41.7% |
| ROE | 1.0% | 16.9% |
| ROA | 0.6% | 10.0% |
| Current Ratio | 4.54x | 1.39x |
| Debt/Equity | 0.54x | 0.10x |
| EPS | $0.16 | $8.87 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCRX vs MSFT: Frequently Asked Questions
Is PCRX or MSFT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. PCRX is rated HOLD (65% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.
How does PCRX compare to MSFT fundamentally?
Pacira BioSciences, Inc. has ROE of 1.0% vs MICROSOFT CORP's 16.9%. Net margins are 1.0% vs 41.7% respectively.
Which stock pays higher dividends, PCRX or MSFT?
PCRX has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCRX or MSFT for long term?
For long-term investing, consider that PCRX has HOLD rating with 65% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCRX vs MSFT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCRX vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.